05-06-2026 16:28 via drugs.com

ASCO: Apalutamide + ADT Beneficial in High-Risk Localized Prostate Cancer

FRIDAY, June 5, 2026-- Perioperative treatment with apalutamide and androgen deprivation therapy (ADT) is beneficial for patients with high-risk localized or locally advanced prostate cancer, according to a study published online June 2 in the New...
Read more »

Pharmaceutical Industry news



ASCO: Tile-Based Radiation Beneficial for Newly Resectable Brain Mets
Wearable Ultrasound Patch Provides Continuous Fetal Monitoring
Cardiometabolic Genetics Linked to Cognitive-Related Outcomes
Dose Reduction of Biologics Effective, Safe for Psoriasis
High Prevalence of Clinical Obesity Seen Even With Normal BMI
FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection
ASCO: Lower Incidence of Breast Cancer Seen With GLP-1 Receptor Agonist Exposure
ASCO: First-Line Sunvozertinib Beats Chemo for Advanced NSCLC
Patients From Most Rural Counties Have Worse Epilepsy Outcomes
2024 Saw Parkinson Disease Death Rate of 72 Per 100,000 Adults Aged 65 and Older
Resistance Training Tied to Lower Risk for Death Across Causes
Gut Microbial, Metabolomic Alterations Persist After Adenoma Resection
Cumulative Attrition for Surgeons 9.7 Percent Over Eight Years
Microbially Derived Metabolites in Urine May Help Identify Autism in Children
Desktop versie